TNF and rheumatoid arthritis: Several published studies have indicated that rituximab in the treatment of RA was a cost-effective treatment alternative with ICERs from $18,348to $41,059 per QALY in comparison with the switch between TNF inhibitors as second line biological treatment [24], [25], [38].